盘龙药业(002864) - 2025 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2025 reached ¥250,212,341.68, representing a 19.08% increase compared to ¥210,115,513.50 in the same period last year[4] - Net profit attributable to shareholders was ¥31,249,274.14, a slight increase of 0.33% from ¥31,147,203.65 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥28,752,863.99, up 18.60% from ¥24,243,406.05 in the previous year[4] - Operating profit for the current period was ¥36,225,272.10, which is a 18.66% increase from ¥30,662,113.08 in the previous period[22] - Net profit for the current period was ¥31,165,841.97, slightly up from ¥31,057,891.33 in the previous period, reflecting a growth of 0.35%[22] Cash Flow - The net cash flow from operating activities decreased significantly by 59.10% to ¥25,964,726.12 from ¥63,478,364.28 in the same period last year[4] - Total cash inflow from operating activities amounted to $281,363,514.11, up from $271,946,168.16, reflecting a growth of 4.9%[26] - Cash outflow from operating activities increased to $255,398,787.99, compared to $208,467,803.88, representing a rise of 22.5%[26] - Cash flow from investing activities showed a net outflow of $22,733,672.35, improving from a net outflow of $47,176,845.97 in the previous period[26] - Cash inflow from financing activities decreased to $50,000,000.00 from $150,000,000.00, a decline of 66.7%[26] - Net cash flow from financing activities was -$6,907,331.39, compared to a positive cash flow of $49,220,138.89 previously[26] - The net increase in cash and cash equivalents was -$3,676,277.62, contrasting with a significant increase of $65,521,657.20 in the prior period[26] Assets and Liabilities - Total assets as of March 31, 2025, were ¥2,316,193,397.43, reflecting a 1.59% increase from ¥2,280,023,009.54 at the end of the previous year[4] - The company's current assets totaled RMB 1,809,097,800.40, compared to RMB 1,771,523,291.39 at the beginning of the period[17] - Total liabilities increased to ¥652,769,648.72 from ¥642,840,255.08, marking a rise of 1.44%[22] - The company’s total liabilities included short-term borrowings of RMB 50,000,000.00, unchanged from the previous period[18] - The company reported a significant increase in contract liabilities by 257.42% to ¥13,136,495.48, primarily due to an increase in advance payments received[7] Inventory and Expenses - The company's inventory increased by 18.35% to ¥113,127,828.48, attributed to higher sales of traditional Chinese medicine products[7] - Research and development expenses rose by 24.87% to ¥4,642,275.19, indicating increased investment in R&D activities[8] - Total operating costs amounted to ¥213,738,632.71, up 19.25% from ¥179,227,823.40 in the prior period[22] - Research and development expenses for the current period were ¥4,642,275.19, up from ¥3,717,714.19 in the previous period, indicating a growth of 24.88%[22] Shareholder Actions - The company completed a share buyback, repurchasing 373,500 shares, which is 0.35% of the total share capital, with a total transaction amount of RMB 10,002,880.25[13] - The share buyback was conducted at a price range between RMB 25.71 and RMB 28.50 per share, with a total planned expenditure between RMB 10 million and RMB 20 million[13] Project Updates - The company decided to terminate the "Shaanxi Province Medical Institution Preparation Center Construction Project" due to lower than expected market size and will use the remaining raised funds to permanently supplement working capital[15] Accounting and Auditing - The company did not undergo an audit for the first quarter report[27] - The new accounting standards will be first implemented starting in 2025[28]